Patients whose brain injury is caused by intracerebral hemorrhage, trauma, and ischemic stroke can benefit from the use of RhinoChill®. This was demonstrated in a study with 15 patients:1,#
iCool** was a pilot study evaluating three different cooling induction methods in patients with ischemic or hemorrhagic stroke. In this randomized trial, 3 methods for rapid cooling of stroke patients were compared: Cold infusions vs. RhinoChill® vs. Sovika® All 3 methods were tested with regard to speed of brain cooling, feasibility and safety.2
RhinoChill® provided selective brain cooling with temperature reductions of 1.8 °C, 1.3°C and 0.8°C in one hour for tympanic, brain, and body, respectively:
* Prospective single-arm safety and feasibility study of intubated patients for whom temperature reduction was indicated. After rhinoscopy, RhinoChill® was activated for 1 hour.1
** Monocentric, prospective, randomized, controlled study involving n=30 intubated and ventilated stroke patients with combined ICP-temperature-probe. The primary endpoint was speed of brain cooling during the first hour. Secondary endpoints were safety aspects (e.g. intracranial bleeding complications, effects on respiration, co-medication). The effects on ICP and cerebral auto-regulation were also examined.2
# In this study 15 patients were enrolled whose brain injury was caused by intracerebral hemorrhage, trauma, and ischemic stroke in equal numbers.
1. Abou-Chebl A, et al. Local brain temperature reduction through intranasal cooling with the RhinoChill® device: preliminary safety data in brain-injured patients. Stroke. 2011 Aug;42(8):2164-2169.
2. Poli S, et al. Induction of Cooling Pilot: A randomized trial comparing 3 methods for rapid cooling of stroke patients: Cold Infusions vs. RhinoChill® vs. Sovika®. Cerebrovasc Dis. 2011;31(suppl 2):219.